Ameliorate chemotherapy-induced intestinal barrier injury; inhibit endotoxemia and elevate the expression of tight junction proteins (E-cadherin, β-catenin, occludin and ZO-1). The gene discussed is TJP1; the disease is serum lipopolysaccharide activity.